Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells
ConclusionProscillaridin A produces anticancer and epigenetic effects in the low nanomolar range and its combination with decitabine warrants further investigation for the treatment of eRMS.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Chemotherapy | Children | Colon Cancer | Colorectal Cancer | Drugs & Pharmacology | Embryonal Carcinoma | Genetics | Heart | Heart Failure | Leukemia | Nanotechnology | Rhabdomyosarcoma